Huatai United Securities Co., Ltd.

About Huaxi Biotechnology Co., Ltd.

Initial public offering and listing on the CRE Board

Summary Report of Sponsor

Name of sponsor Huatai United Securities Co., Ltd.

Sponsor No. Z26774000

1. Sponsor and Sponsor Representative Commitment

1. There are no false records, misleading statements or material omissions in the contents of the sponsor summary report and supporting documents and related materials, and the sponsor and the sponsor representative shall bear legal responsibility for their authenticity, accuracy and completeness.

2. This institution and I voluntarily accept any inquiries and investigations conducted by the China Securities Regulatory Commission (hereinafter referred to as the "China Securities Regulatory Commission") and the Shanghai Stock Exchange on matters related to the recommendation summary report.

3. This institution and I voluntarily accept the regulatory measures taken by the China Securities Regulatory Commission in accordance with the relevant provisions of the Measures for the Administration of Securities Issuance and Listing Sponsorship Business.

Basic Information of 2. Sponsor Institutions

Content of the situation

Name of sponsor Huatai United Securities Co., Ltd.

Registered Address: Qianhai Shenzhen-Hong Kong Fund, 128 Guiwan Fifth Road, Nanshan Street, Qianhai Shenzhen-Hong Kong Cooperation Zone, Shenzhen

401, Building B7, Small Town

Main office address: Floor 6, Block B, Fengming International Building, No.20 Fengsheng Hutong, Xicheng District, Beijing

Legal Representative Jiang Yu

Contacts Qi Yuqian and Lu Yugang

Contact numbers 010-56839300, 021-38966588

3. Issuer Basic Information

Content of the situation

Name of Issuer Huaxi Biotechnology Co.

Stock code 688363.SH

Registered capital 481,085,277 yuan

Registered address: 678 Tianchen Street, High-tech Development Zone, Jinan City, Shandong Province

Main office address: 678 Tianchen Street, High-tech Development Zone, Jinan City, Shandong Province

Legal Representative Zhao Yan

Actual controller Zhao Yan

Contact Li Yizheng

Contact number 010-85670603

This securities issue type initial public offering of shares and listing on the board.

The securities were issued on October 24, 2019.

This securities listing time November 6, 2019.

The securities are listed on the Shanghai Stock Exchange.

2019 Annual Report disclosed on 29 April 2020

Annual Report Disclosure Time 2020 Annual Report Disclosure March 31, 2021

2021 Annual Report disclosed on March 11, 2022

2022 Annual Report disclosed on March 31, 2023

Overview of 4. recommendation work

Project work content

In accordance with relevant laws and regulations, conduct due diligence on the issuer's situation and organize

Prepare application documents and issue recommendation documents; after submitting recommendation documents, actively cooperate with Shanghai

Stock exchange audit, CSRC registration related work, organization of issuers and other

1, due diligence recommendation work intermediary agencies to the Shanghai Stock Exchange, the China Securities Regulatory Commission's opinion to reply, in accordance.

The requirements of the Shanghai Stock Exchange and the China Securities Regulatory Commission are related to the issuance and listing of securities.

Due diligence or verification of specific matters, and with the Shanghai Stock Exchange, China Securities.

The Supervisory Board conducts professional communication, in accordance with the requirements of the listing rules of the stock exchange to the stock exchange.

The Exchange shall submit the relevant documents recommending the listing requirements of the shares and report them to the CSRC for the record.

2. Continuous supervision period

(1) The information disclosure documents during the continuous supervision period of the company's information disclosure review shall be carefully reviewed by the company's sponsor representative.

After reading the situation, report to the exchange announcement.

(2) Training situation The sponsor representative on March 13, 2020 to the issuer's directors, supervisors, high

On-site training was conducted for senior management personnel and key post personnel.

Project work content

(3) Supervise the company to establish health.

Continuous improvement and effective implementation of corporate governance and internal control systems during the period of full and effective implementation of rules and regulations,

(including the prevention of related parties, including but not limited to the financial management system, accounting system, internal audit system, the system of using the company's resources, internal and related transactions, external guarantees, foreign investment and other major business decision-making procedures and rules control degree, internal audit system, etc.

degree, related transaction system, etc.)

Situation

The issuer raised capital under the China Securities Regulatory Commission and the Shanghai Stock Exchange listed company.

The relevant provisions of the fund management opened a special fund-raising account, the establishment of a fund-raising account.

Storage system, and with the sponsor institutions, relevant commercial banks signed a special fund-raising account supervision.

tube agreement. The sponsor representative supervises and inspects the statements sent regularly by commercial banks.

(4) Supervised the company to establish the use of fund-raising funds, and regularly went to the issuer's site to check the storage and use of the fund-raising funds special account storage system.

The net amount of funds raised by the issuer in this initial public offering is as follows

The situation of Jin's special account is 2,248,954,425.00 yuan, which is invested in the "upgrading and renovation project of Huaxi Biological Research and Development Center",

"Huaxi Tianjin Sodium Hyaluronate and Related Projects" and "Huaxi Biological Life Health Industry"

The park project ". As of December 31, 2022, the company's raised funds have been invested cumulatively.

2,009,610,643.31 yuan, the balance of the special account for raised funds is 334,525,310.58 yuan

(including interest and financial income, less fee expenses).

During the continuous supervision period, the sponsor representative attended some of the on-site meetings of the issuer.

(5) Attend the general meeting of the board of directors of the company to understand whether the convening, convening and voting of the "three meetings" of the issuer are in accordance with the law.

and the provisions of the General Meeting of Shareholders and the Articles of Association of the Company, to understand the decision-making status of the Issuer's material matters. Right.

At meetings where the sponsor representative is unable to attend, the sponsor representative shall review the meeting in advance.

know, issues, through e-mail, telephone and other means to supervise the issuer to convene in accordance with the provisions.

During the continuous supervision period, in 2019-2022, the sponsor issued a separate statement on the issuance of

The special verification report on the deposit and use of the annual fund-raising funds of the issuer holds that: the issuer

(6) There is no illegal use of funds raised from the initial public offering of A- shares by the sponsor. Continued

During the period of supervision of the establishment of opinions, the sponsor institution shall have a view on the use of funds raised by the issuer, related transactions and restricted shares.

Listed circulation, core technical personnel departure and other matters, issued 29 verification opinions, no.

Make disagreeable comments.

(7) Tracking the fulfillment of commitments During the continuous supervision period, the sponsor representative continued to pay attention to and urge the issuer and the holding company.

The issuer and its shareholders and actual controllers shall earnestly fulfill the commitments related to the issuance.

His relevant personnel can effectively fulfill their commitments.

(8) The sponsor institution cooperates with the delivery.

The work of the Exchange (including the timely submission of continuous supervision documents by the sponsor to the Exchange during the continuous supervision period,

There are no other circumstances that require the sponsor to cooperate with the work of the exchange.

Send documents, etc.)

(9) Other None.

5. the major matters and handling of the sponsor during the performance of the sponsor's duties.

None.

The 6. cooperates with the listed company to protectDescription and evaluation of recommended work

1. Due diligence recommendation stage: the issuer can provide the sponsor and other intermediary agencies with the documents, materials and relevant information required for this issuance in a timely manner in accordance with relevant laws and regulations, and ensure that the documents, materials and information provided are true, accurate and complete, There are no false records, misleading statements or major omissions; in accordance with the requirements of relevant laws and regulations, actively cooperate with the due diligence verification work of this sponsor, it provides the necessary conditions and facilities for the recommendation of this stock issue and listing.

2. Continuous supervision stage: the issuer can operate in accordance with the requirements of relevant laws and regulations, and disclose external information in a timely and accurate manner in accordance with the requirements of relevant laws and regulations; important matters can be notified to the sponsor in a timely manner and communicate with the sponsor Representative, and at the same time provide relevant documents and materials in a timely manner according to the requirements of the sponsor, it ensures that the sponsor and its sponsor representative make timely suggestions and professional opinions on relevant major matters.

7.'s explanation and evaluation of the work related to the participation of securities service institutions in securities issuance and listing.

(1) Due diligence recommendation stage: the intermediary engaged by the issuer can issue professional opinions in accordance with the provisions of relevant laws and regulations, and can actively cooperate with the coordination and verification work of the sponsor.

(2) Continuous supervision stage: the intermediary engaged by the issuer can issue professional opinions in a timely manner in accordance with the requirements of relevant laws and regulations.

Concluding Opinions of the 8. on the Review of Information Disclosure of Listed Companies

The sponsor believes that the announcement disclosed by the issuer is consistent with the actual situation, the disclosure is complete, and there are no matters that should be disclosed but not disclosed.

Concluding Opinions of the 9. on the Review of the Use of Funds Raised by Listed Companies

The sponsor believes that the issuer is used in strict accordance with the relevant regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange.

The funds raised have effectively implemented the tripartite supervision agreement, and performed the relevant information disclosure work in a timely, true, accurate and complete manner, and there is no illegal use of the funds raised.

10. other matters required by the China Securities Regulatory Commission and the Shanghai Stock Exchange

As of December 31, 2022, Huaxi Bio's initial public offering of shares has not yet been used up.

As the sponsor of Huaxi Bio's issuance, Huatai United Securities will continue to perform continuous supervision responsibility on the storage and use of the funds raised in Huaxi Bio's issuance until the use of the funds raised is completed.